1. A method for manufacturing a three-dimensional shaped object, the method comprising repeatedly:
forming a solidified layer by irradiating a predetermined portion of a powder layer with a light beam, thereby allowing a sintering of the powder in the predetermined portion or a melting and subsequent solidification thereof; and
forming another solidified layer by newly forming a powder layer on the resulting solidified layer, followed by the irradiation of a predetermined portion of the powder layer with the light beam,
wherein a part of a surface portion of the three-dimensional shaped object is formed as a low-density solidified portion whose solidified density ranges from 50% to 90% so that an application of pressure can be performed by a gas flowing through the low-density solidified portion;
and the method further comprising:
forming a hollow portion in the three-dimensional shaped object such that the hollow portion communicates with the low-density solidified portion; and
forming, in a partial space of the hollow portion, a supporting solidified portion defined by a sintered portion, wherein the supporting solidified portion supports and is connected to the low-density solidified portion.
2. The method according to claim 1, wherein the low-density solidified portion with its thickness of 0.5 to 10 mm is formed.
3. A three-dimensional shaped object obtained by the method according to claim 1, used as a core metal mold or a cavity metal mold;
wherein at least a part of a cavity-forming surface of the metal mold is provided with a low-density solidified portion whose solidified density ranges from 50% to 90%, and thereby an application of pressure with respect to a raw material for molding or a molded article can be performed by a gas flowing through the low-density solidified portion.
4. The three-dimensional shaped object according to claim 3, further comprising the hollow portion, which is in communication with the low-density solidified portion, being provided in communication with an outside of the shaped object.
5. The three-dimensional shaped object according to claim 3, wherein a thickness of the low-density solidified portion is locally different.
6. A method for manufacturing a molded article by using of the three-dimensional shaped object obtained by the method according to claim 1 as a metal mold, the method comprising:
injecting a raw resin material into a cavity of the metal mold; and
subjecting the raw resin material to a molding process in the cavity of the metal mold;
wherein pressure is applied from the outside of the cavity with respect to the raw resin material or a molded article obtained therefrom by supplying a gas via the low-density solidified portion.
7. The method according to claim 6, wherein a temperature of the raw resin material or the molded article in the cavity is adjusted by making use of a temperature of the gas.
8. The method according to claim 6, wherein the application of the pressure by the gas supply is performed in each of an injectionpressure-keeping process and a demold process, the pressure being gas pressures different from each other with respect to the injectionpressure-keeping process and the demold process.
9. The method according to claim 1, comprising the supporting solidified portion being formed by a plurality of spaced apart sintered portions.
10. The method according to claim 9, wherein the plurality of spaced apart sintered portions is spaced apart at regular intervals.
11. The method according to claim 9, wherein ends of the plurality of spaced apart sintered portions support the low-density solidified portion such that the low-density solidified portion is positioned above the plurality of spaced apart sintered portions that are provided within the hollow portion.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treatment of colorectal cancer, comprising:
administering to a patient afflicted with colorectal cancer picoplatin, 5-fluorouracil (5-FU), and leucovorin, wherein 5-FU and leucovorin are administered intravenously at least twice at intervals of about 2-6 weeks and the picoplatin is administered with the leucovorin and 5-FU every other time that the fluorouracil and leucovorin are administered.
2. The method of claim 1, wherein the picoplatin is administered at a dose of about 60-180 mgm2, preferably at a dose of about 150 mgm2.
3. The method of claim 1, wherein the interval of administration of the 5-FU and the leucovorin is about two weeks and the interval of administration of the picoplatin is about four weeks.
4. A method of treatment of colorectal cancer, comprising:
administering to a patient afflicted with colorectal cancer effective amounts of a combination of picoplatin, 5-FU and leucovorin, wherein the picoplatin, 5-FU and leucovorin are administered intravenously at least twice at intervals of about two weeks, wherein the amount of picoplatin is less than the maximum tolerated dose of picoplatin when administered in said combination.
5. The method of claim 4, wherein the picoplatin is administered at a dose of about 45-150 mgm2, preferably at a dose of about 135-150 mgm2.
6. The method of claim 4, wherein the interval of administration of the picoplatin, 5-FU and the leucovorin is about two weeks.
7. A method for selecting a regimen of treatment for a patient afflicted with mCRC comprising; (a) identifying a patient afflicted with mCRC, (b) determining if the mCRC comprises a wild type K-ras gene or a mutated K-ras gene and (c) if the mCRC comprises a K-ras mutation positive genotype, then administering at least twice to the patient picoplatin and, optionally, 5-FU and leucovorin.
8. The method of claim 1 wherein the patient has not previously been treated for metastatic disease.
9. The method of claim 1 wherein the patient has not previously been treated systemically.
10. The method of claim 1 wherein the patient has previously had surgery to remove or de-bulk a colorectal tumor.
11. The method of claim 1 wherein the administration is effective to prevent or delay development or metastasis of the colorectal cancer.
12. The method of claim 1 wherein the picoplatin, when administered, and the leucovorin are administered substantially concurrently.
13. The method of claim 1 wherein the picoplatin, when administered, and the leucovorin are administered simultaneously.
14. The method of claim 1 wherein the 5-FU is administered following the administration of the picoplatin and the leucovorin.
15. The method of claim 4 wherein the picoplatin is administered substantially concurrently with the leucovorin followed by administration of the 5-FU at every treatment of the patient.
16. The method of claim 1 wherein the leucovorin is administered at a dosage of about 400 mgm2.
17. The method of claim 1 wherein the 5-FU is administered at a total dosage per dosing of about 2000-3000 mgm2.
18. The method of claim 1 wherein the picoplatin is administered at a dosage of about 60-180 mgm2.
19. The method of claim 18 wherein the picoplatin is administered at a dosage of about 120-180 mgm2.
20. The method of claim 1 wherein a subsequent dose of picoplatin is administered at about a 15-30 mgm2 lower dose than a previous dose.
21. The method of claim 18 wherein the picoplatin is administered at least once at a dosage of about 150 mgm2.
22. The method of claim 1 wherein the picoplatin is administered at least once at a dosage of about 60-75 mgm2.
23. The method of claim 4 wherein the picoplatin is administered at least once at a dosage of about 40-45 mgm2.
24. The method of claim 1, wherein a cumulative dose of greater than about 900 mgm2 of picoplatin is delivered to the patient.
25. The method of claim 1 wherein the leucovorin, at a dosage of about 400 mgm2, is administered as a 2 hour infusion, the administration of the leucovorin being followed by a 5-FU bolus at a dosage of about 400 mgm2; the 5-FU bolus being followed by 5-FU at a dosage of about 2,400 mgm2 administered as a 46 hour continuous infusion; wherein the leucovorin and the 5-FU are administered to the patient every 2 weeks and about 60-150 mgm2 of the picoplatin is administered to the patient with the leucovorin every 4 weeks, wherein at least the initial dose of picoplatin is about 150 mgm2.
26. The method of claim 1 further comprising administration of a 5-HT3 receptor antagonist.
27. The method of claim 1 comprising administering the picoplatin in a dosage form comprising an isotonic solution comprising,
(a) water;
(b) a tonicity adjuster; and
(c) about 0.5 mgmL dissolved picoplatin.